Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Home

Marketplace
Database
News
Store
Resources
Contact Us

 

 

News


VENTURE CAPITAL DIRECTORY | PRIVATE EQUITY DIRECTORY

List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory

2021 NEW EDITION NOW AVAILABLE!
Buy Now for $119.95 with a free annual update in January 2022

Learn More or Buy Now

VCPro Database 2021 24th Edition -- a downloadable and searchable venture capital database with 6,500+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. (Updated JULY 2021)

Learn More » or Buy Now »




AgBiome Raises $116 Million Led By Blue Horizon and Novalis LifeSciences

AgBiome's Best-in-Class Microbial Platform Delivers Crop Protection Solutions to Feed the Growing Population Responsibly

RESEARCH TRIANGLE PARK, N.C., September 14, 2021-- AgBiome, the leader in developing innovative products from the Earth's microbial communities, announced it has raised $116 million in an oversubscribed Series D round of funding, co-led by Blue Horizon and Novalis LifeSciences and that included multiple new and existing investors. The company will use the capital to expand more rapidly its product portfolio, scale its scientific and commercial teams, and continue to build its global presence and partnerships.

The growing global population, increased demand for clean, healthy food, and pressure to reduce chemical agricultural applications have created a need for sustainable and environmentally compatible crop protection. AgBiome's mission is to develop and deliver naturally derived crop protection products that meet grower need and consumer desire for sustainable food production.

AgBiome has a strong product pipeline to serve the growing global demand for biological alternatives. Its first product, Howler® fungicide, is a revolutionary biological that harnesses the power of the plant microbiome and works on more than 300 crop-disease combinations. It offers multiple modes of action to provide preventive, long-lasting activity on a broad spectrum of soilborne and foliar diseases and demonstrated 10x sales growth in 2020.

The company expects to launch its second product, Theia™ Fungicide in early 2022, and recently submitted its third product, Esendo™ Fungicide for EPA registration. Starting with biological fungicides and expanding to insecticides and herbicides, the company will have launched 11 products by 2025.

"Biologicals are a rapidly growing, disruptive market segment that is projected to grow 14-fold by 2030," said Scott Uknes, Co-Founder and Co-CEO of AgBiome. "Growers need new tools to control problematic diseases while ensuring effective resistance management. AgBiome is laser focused on developing those science-based solutions. With this capital, AgBiome is well positioned to execute on its strategic business model focused on developing proprietary products, fostering partner programs, joint ventures, and new company formations, all of which represent significant growth opportunities for AgBiome," added Uknes.

"The impact of synthetic pesticides on the environment and human health is in the spotlight like never before, with customers and lawmakers alike demanding alternatives," said Przemek Obloj, Managing Partner at Blue Horizon. "AgBiome provides that alternative: biological products that match the efficacy and cost of synthetic chemicals without the negatives. AgBiome helps realize Blue Horizon's goal to accelerate the transition to a sustainable food system; we are thrilled to be able to support the Company and its experienced team."

"As one of the leading innovators in the biologics crop protection space, this significant fundraising will allow AgBiome to rapidly accelerate its mission to feed the world responsibly by both discovering and developing its own products as well as by identifying strategic acquisition growth opportunities," said Marijn Dekkers, Chair of Novalis LifeSciences and Chair of the AgBiome Board.

As part of its integrated approach to crop protection, AgBiome partners with global ag companies to accelerate innovation, research and product commercialization and distribution. AgBiome has multiple significant commercial agreements with South Korea's Farm Hannong, TMG in Brazil, Sumitomo Corp in Mexico, SePro Corporation, and research collaborations with BASF, Genective, Mosaic, Elanco, Bill & Melinda Gates Foundation, the Max Planck Institute, and ElevateBio.

Cascadia Capital, an investment bank providing merger and acquisition, capital raising and strategic advisory services, acted as a placement agent for this transaction.

About AgBiome

AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiaries, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops. In 2021, AgBiome was recognized by Inc. Magazine as a Best Place to Work. AgBiome's additional investors include Polaris Partners, ARCH Venture Partners, Fidelity Investments Inc., UTIMCO, Pontifax AgTech, Novalis LifeSciences, Innotech Advisors, Syngenta Ventures, Leaps by Bayer, and Novozymes. For more information, visit http://agbiome.com.


News Index

Venture Capital Database 

 

 NEWS

Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Business Plan Tools

Free Business Plan Template

 

Copyright © 1998-2021 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer